Search results for "Cutaneous"

showing 10 items of 1022 documents

Percutaneous angioplasty and stenting of left subclavian artery lesions for the treatment of patients with concomitant vertebral and coronary subclav…

2006

bjective: To evaluate the efficacy of subclavian stenosis percutaneous transfemoral angioplasty (PTA)-treatment in patients with intermittent or complete subclavian steal syndrome (SSS), and coronary-subclavian steal syndrome (C-SSS) after left internal mammary artery-interventricular anterior artery (LIMA-IVA) by pass graft. Methods: We studied 42 patients with coronary subclavian steal syndrome subdivided in two groups; the first group consisted of 15 patients who presented an intermittent vertebral-subclavian steal, while the second group consisted of 27 patients with a complete vertebral-subclavian steal. All patients were treated with angioplasty and stent application and were followed…

Malemedicine.medical_specialtyPercutaneousmedicine.medical_treatmentVertebral arterySubclavian ArteryBalloonSubclavian Steal SyndromeRisk FactorsInternal medicinemedicine.arteryAngioplastymedicineHumansRadiology Nuclear Medicine and imagingcardiovascular diseasesInternal Mammary-Coronary Artery Anastomosishealth care economics and organizationsSubclavian arteryVertebral ArteryAgedChi-Square Distributionmedicine.diagnostic_testbusiness.industryAngiographyUltrasonography DopplerMiddle Agedmedicine.diseaseSurgerybody regionssurgical procedures operativemedicine.anatomical_structureTreatment OutcomePercutaneous angioplasty and stenting of left subclavian artery lesions vertebral and coronary subclavian steal syndrome.Angiographycardiovascular systemCardiologyFemaleStentsCardiology and Cardiovascular MedicinebusinessSubclavian steal syndromeAngioplasty BalloonArteryCardiovascular and interventional radiology
researchProduct

Temporal retrogasserian resection of trigeminal root versus controlled elective percutaneous electrocoagulation of the ganglion of gasser in the trea…

1972

In his experience with 531 surgical procedures for the relief of trigeminal neuralgia between 1955 to 1970, the author developed a strong preference for the percutaneous electro-coagulation of the gasserian ganglion. Although the method was repeatedly modified in the early years, a standardized technique of controlled, selective and fractional coagulation in the semiawake state of neurolept-anaesthesia was used since 1963 in 183 of his 311 patients, treated in this manner. The advantages of the method, particularly in comparison to open intracranial root sections, are: Minimal operative risk, control of operative effect during the operation, small sensibility deficit, low rate of complicati…

Malemedicine.medical_specialtyPercutaneousmedicine.medical_treatmentmedia_common.quotation_subjectElectrocoagulationStereotaxic TechniquesThalamusTrigeminal neuralgiaMesencephalonmedicineElectrocoagulationMethodsHumansTrigeminal Nervemedia_commonNeuroradiologyMedulla Oblongatamedicine.diagnostic_testbusiness.industryConvalescenceInterventional radiologyTrigeminal Neuralgiamedicine.diseaseSurgeryGanglionmedicine.anatomical_structureEvaluation Studies as TopicAnesthesiaSurgeryNeurology (clinical)NeurosurgerybusinessCraniotomyActa neurochirurgica
researchProduct

A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions

2018

Aims: The clinical value of percutaneous coronary intervention (PCI) for chronic coronary total occlusions (CTOs) is not established by randomized trials. This study should compare the benefit of PCI vs. optimal medical therapy (OMT) on the health status in patients with at least one CTO.Method and results: Three hundred and ninety-six patients were enrolled in a prospective randomized, multicentre, open-label, and controlled clinical trial to compare the treatment by PCI with OMT with a 2:1 randomization ratio. The primary endpoint was the change in health status assessed by the Seattle angina questionnaire (SAQ) between baseline and 12 months follow-up. Fifty-two percent of patients have …

Malemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyAngina Pectorislaw.inventionAngina03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRandomized controlled triallawInternal medicinemedicineClinical endpointHumansPercutaneous transluminal interventioncardiovascular diseases030212 general & internal medicineMyocardial infarctionOptimal medical therapyAgedNitratesbusiness.industryAngina PectoriPercutaneous coronary interventionAngiotensin-Converting Enzyme InhibitorMiddle Agedmedicine.diseaseClinical trialCoronary OcclusionChronic coronary occlusion; EQ-5D; Optimal medical therapy; Percutaneous transluminal intervention; Seattle angina questionnaire; Cardiology and Cardiovascular MedicineConventional PCIChronic DiseaseChronic coronary occlusionQuality of LifeSeattle angina questionnaireFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitors
researchProduct

Can sentinel node biopsy be safely omitted in thin melanoma? Risk factor analysis of 1272 multicenter prospective cases

2019

Background: The indication to sentinel node biopsy (SNB) for thin melanomas (Breslow <1 mm) is still subject to controversies. The aim of this paper is to review all SNB performed for thin melanoma and to analyze factors related to lymphatic metastasis. Moreover, the diagnostic performance of the 5th, 6th, 7th and 8th AJCC classifications for cutaneous melanoma were investigated. Methods: All sentinel node biopsies performed for thin melanomas were selected from a multicentre prospectively-collected database. For each patient the following was collected: age, sex, date of treatment, site of primary melanoma, histopathologic features (Breslow, Clark, number of mitoses/mm2 , presence of ul…

Malemedicine.medical_specialtySkin NeoplasmsMultivariate analysisRisk AssessmentBreslow Thickness03 medical and health sciencesMelanoma; Sentinel node; Sentinel node biopsy; Thin melanoma0302 clinical medicineRisk FactorsBiopsyHumansMedicineProspective Studies030212 general & internal medicineSkin NeoplasmRisk factorProspective cohort studyMelanomaThin melanomaSentinel node biopsyMelanoma; Sentinel node; Sentinel node biopsy; Thin melanoma; Surgery; Oncologymedicine.diagnostic_testbusiness.industrySentinel Lymph Node BiopsyMelanomaRisk FactorLymphatic MetastasiGeneral MedicineSentinel nodeMiddle Agedmedicine.diseaseProspective StudieOncologySentinel nodeLymphatic Metastasis030220 oncology & carcinogenesisCutaneous melanomaSurgeryFemaleRadiologybusinessHuman
researchProduct

A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminol…

2018

Background: Basal cell carcinoma (BCC) represents the most common nonmelanoma skin cancer worldwide, affecting mainly adult, fair-skinned individuals. The World Health Organization distinguishes aggressive and nonaggressive forms, of which prototypical variants of the latter are primary nodular and superficial BCC. Objective: To demonstrate noninferiority of BF-200 ALA (a nanoemulsion gel containing 5-aminolaevulinic acid) compared with MAL (a cream containing methyl aminolaevulinate) in the treatment of nonaggressive BCC with photodynamic therapy (PDT). Noninferiority of the primary efficacy variable (overall patient complete response 12 weeks after last PDT) would be declared if the mean …

Malemedicine.medical_specialtySkin Neoplasmsmedicine.medical_treatmentSkin CreamPhotodynamic therapyDermatologyAdministration Cutaneouslaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled trialMethyl aminolevulinatelawCarcinomaHumansMedicineBasal cell carcinomaAgedSkinPhotosensitizing Agentsbusiness.industryActinic keratosisAminolevulinic AcidMiddle Agedmedicine.diseaseDermatologyClinical trialTreatment OutcomePhotochemotherapyCarcinoma Basal Cell030220 oncology & carcinogenesisFemaleSkin cancerbusinessmedicine.drugBritish Journal of Dermatology
researchProduct

Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inf…

2015

AbstractZostavax® is a live, attenuated varicella zoster virus (VZV) vaccine developed specifically for the prevention of HZ and PHN in individuals aged ≥50 years. During the clinical development of Zostavax, which was mainly in the US, the vaccine was administrated by the subcutaneous (SC) route. In Europe, many healthcare professionals prefer administering vaccines by the intramuscular (IM) route. This was an open-label, randomised trial conducted in 354 subjects aged ≥50 years. The primary objectives were to demonstrate that IM administration is both non-inferior to SC administration in terms of 4-week post-vaccination geometric mean titres (GMTs), and elicits an acceptable geometric mea…

Malemedicine.medical_specialtySub-cutaneous administration routeEnzyme-Linked Immunospot AssayHerpesvirus 3 HumanInjections SubcutaneousVaricella zoster virus vaccinePainmedicine.disease_causeAntibodies ViralVaccines AttenuatedHerpes ZosterInjections Intramuscularlaw.inventionShinglesInterferon-gammaRandomized controlled triallawImmunology and Microbiology(all)Internal medicinemedicineEdemaHerpes Zoster VaccineHumansAdverse effectAgedRandomised controlled trialAged 80 and overAttenuated vaccineIntention-to-treat analysisGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryELISPOTImmunogenicityVaccinationPublic Health Environmental and Occupational HealthVaricella zoster virusIntramuscular administration routeMiddle Agedmedicine.diseaseveterinary(all)Infectious DiseasesErythemaImmunologyMolecular MedicineFemalebusinessShinglesVaccine
researchProduct

Programmed death-1 (PD-1): A novel mechanism for understanding the acute immune deregulation in ST-segment elevation myocardial infarction

2014

Malemedicine.medical_specialtySwinemedicine.medical_treatmentProgrammed Cell Death 1 ReceptorMyocardial InfarctionPercutaneous Coronary InterventionImmune systemInternal medicinemedicineAnimalsHumansST segmentProspective StudiesMyocardial infarctionAgedMechanism (biology)business.industryPercutaneous coronary interventionMiddle Agedmedicine.diseaseProgrammed Cell Death 1 ReceptorCardiologyFemaleProgrammed death 1ComprehensionCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Sudden infant death caused by a ruptured coronary aneurysm during acute phase of atypical Kawasaki disease

2001

This article describe's a case of atypical Kawasaki disease (AKD) with lack of typical clinical signs and rapid fatal course in a 2-month-old infant, who 1 week before hospitalization demonstrated rhinitis, coughing without fever, and later conjunctival hyperemia and allergic exanthema on chest and arms. On admittance, labwork highlighted the following: leukocytosis, thrombocytosis, elevated sedimentation rate, and positive C-reactive protein. General conditions remained mediocre for 7 days until sudden death occurred. The autopsy confirmed death caused by cardiac tamponade caused by a ruptured inflammated aneurysm of the left anterior descending coronary artery. We believe that the current…

Malemedicine.medical_specialtyThrombocytosisbusiness.industryVascular diseaseCoronary AneurysmInfantAutopsyMucocutaneous Lymph Node Syndromemedicine.diseaseSudden deathPathology and Forensic MedicineSurgeryFatal OutcomeCardiac tamponadeAcute DiseasemedicineHumansKawasaki diseaseLeukocytosismedicine.symptombusinessComplicationSudden Infant DeathHuman Pathology
researchProduct

Real-world use of ticagrelor and prasugrel in patients with NSTEMI undergoing percutaneous coronary intervention.

2017

Malemedicine.medical_specialtyTicagrelorPrasugrelAdenosinemedicine.medical_treatmentTreatment outcomeMEDLINE030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicinemedicineHumansIn patient030212 general & internal medicineNon-ST Elevated Myocardial InfarctionAgedRetrospective Studiesbusiness.industryPercutaneous coronary interventionRetrospective cohort studyGeneral MedicineMiddle AgedNSTEMITreatment OutcomeEmergency medicineCardiologyPurinergic P2Y Receptor AntagonistsObservational studyFemalebusinessCardiology and Cardiovascular MedicineTicagrelorPrasugrelPrasugrel Hydrochloridemedicine.drugJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings

2006

Background: There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12–72 h). Methods: 451 reperfused STEMI patients, a…

Malemedicine.medical_specialtyTiclopidineTime Factorsmedicine.medical_treatmentMyocardial InfarctionFacilitated Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexGIIb/IIIa inhibitorDelayed Percutaneous Coronary InterventionsInternal medicineAngioplastymedicineAbciximabAcute myocardial InfarctionHumanscardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryAnticoagulantsPercutaneous coronary interventionHematologyTirofibanMiddle AgedClopidogrelmedicine.diseaseCombined Modality TherapyClopidogrelsurgical procedures operativeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsCombined therapyPlatelet Aggregation InhibitorsTIMIFollow-Up Studiesmedicine.drugJournal of Thrombosis and Thrombolysis
researchProduct